feedback

Course Director

Leora Horn, MD, MSc, FRCPC
Leora Horn, MD, MSc, FRCPC

Vanderbilt Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, Tennessee

Faculty

Kristin Higgins
Kristin Higgins, MD

Emory University School of Medicine
Winship Cancer Institute
Atlanta, Georgia

Onkar V. Khullar
Onkar V. Khullar, MD

Emory University School of Medicine
Winship Cancer Institute
Atlanta, Georgia

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CNE
Credit Amount:1.5 Credits
Release Date:2019-May-09
Expiration Date:2020-May-08
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides practical guidance on how to transition immunotherapy into earlier stages of lung cancer in this MasterClass and Practicum.

Upon completion of this activity, participants will be able to:
  • Discuss the rationale for use, mechanisms of action, and role of immunotherapy in the management of lung cancer
  • Assess the latest data on the efficacy and safety of immunotherapy in stage III NSCLC, and the clinical implications of these data
  • Describe key trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer
  • Incorporate immunotherapy into treatment plans for patients with locally advanced or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and co-ordination of care

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, thoracic surgeons, nurses, and other multidisciplinary clinicians involved in the management of patients with lung cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 09, 2019 - May 08, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

Course Director

Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director Thoracic Oncology Program
Vanderbilt Ingram Cancer Center
Assistant Vice Chairman for Faculty Development
Vanderbilt University Medical Center
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bristol-Myers Squibb; EMD Serono, Inc.; Genentech, Inc.; Incyte Corporation; Merck & Co., Inc.; Tesaro, Inc.; and Xcovery.

Leora Horn, MD, MSc, FRCPC, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Cancer immunotherapies and/or immunotherapy-based combinations.

Faculty

Kristin Higgins, MD
Associate Professor
Emory University School of Medicine
Medical Director, Dept of Radiation Oncology
Winship Cancer Institute
Atlanta, Georgia

Kristin Higgins, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Genentech, Inc.; and Varian.
Grant/Research Support from RefleXion Medical.

Kristin Higgins, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Cancer immunotherapies and/or immunotherapy-based combinations.

Onkar V. Khullar, MD
Assistant Professor of Surgery, Division of Cardiothoracic Surgery, Department of Surgery
Emory University School of Medicine
Winship Cancer Institute
Atlanta, Georgia

Onkar V. Khullar, MD, has no financial interests/relationships or affiliations in relation to this activity.

Onkar V. Khullar, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Cancer immunotherapies and/or immunotherapy-based combinations.

Content Reviewers

Siyang Leng, MD, has no financial interests/relationships or affiliations in relation to this activity.

Tracy L. Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Janice Trainor-Tellier, MSN, RN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Kristin Tomlinson, PhD
PVI, PeerView Institute for Medical Education

Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.5 contact hour(s).

Providership



This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.